Literature DB >> 20733451

Relationships between cell-free DNA and serum analytes in the first and second trimesters of pregnancy.

Neeta L Vora1, Kirby L Johnson, Geralyn Lambert-Messerlian, Hocine Tighiouart, Inga Peter, Adam C Urato, Diana W Bianchi.   

Abstract

OBJECTIVE: To assess the relationship between first- and second-trimester cell-free DNA levels and maternal serum screening markers.
METHODS: First- and second-trimester residual maternal serum samples from 50 women were obtained. First-trimester (pregnancy-associated plasma protein A and beta-hCG) and second-trimester serum analytes (beta-hCG, alpha-fetoprotein, unconjugated estriol, and inhibin A) had been measured at the time of sample receipt. All fetuses were male as confirmed by birth records. Cell-free DNA was extracted and measured by real-time quantitative polymerase chain reaction amplification using glyceraldehyde phosphate dehydrogenase and DYS1 as markers of total DNA and fetal DNA, respectively. Determination of linear associations between first- and second-trimester serum markers and cell-free DNA levels using Pearson correlations was performed.
RESULTS: Statistically significant correlations between first-trimester pregnancy-associated plasma protein A multiples of the median and both total (r=0.36, P=.016) and fetal (r=0.41, P=.006) DNA in the first trimester were observed. There were no significant correlations between first-trimester serum human chorionic gonadotropin or any second-trimester serum marker with DNA levels.
CONCLUSION: Correlation between serum pregnancy-associated plasma protein A and first-trimester circulating cell-free fetal and total DNA levels is a novel finding. Pregnancy-associated plasma protein A is a glycoprotein of placental origin, and its correlation to cell-free fetal DNA in maternal serum suggests a common tissue origin through apoptosis of placental cells. However, because pregnancy-associated plasma protein A and cell-free DNA were only marginally correlated and cell-free DNA can be reliably detected in the first trimester, the addition of cell-free DNA to serum screening strategies may be helpful in predicting adverse pregnancy outcome. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20733451      PMCID: PMC2975594          DOI: 10.1097/AOG.0b013e3181ea2dd1

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  29 in total

1.  Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia.

Authors:  T N Leung; J Zhang; T K Lau; L Y Chan; Y M Lo
Journal:  Clin Chem       Date:  2001-01       Impact factor: 8.327

2.  First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).

Authors:  N J Wald; C Rodeck; A K Hackshaw; J Walters; L Chitty; A M Mackinson
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

3.  Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down syndrome pregnancy.

Authors:  Antonio Farina; Erik S LeShane; Geralyn M Lambert-Messerlian; Jacob A Canick; Thomas Lee; Louis M Neveux; Glenn E Palomaki; Diana W Bianchi
Journal:  Clin Chem       Date:  2003-02       Impact factor: 8.327

Review 4.  Fetal cell-free nucleic acids in the maternal circulation: new clinical applications.

Authors:  Tuangsit Wataganara; Diana W Bianchi
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

5.  Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia.

Authors:  Y M Lo; T N Leung; M S Tein; I L Sargent; J Zhang; T K Lau; C J Haines; C W Redman
Journal:  Clin Chem       Date:  1999-02       Impact factor: 8.327

6.  Pregnancy-associated plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by degrading IGFBP-4 in vitro.

Authors:  D Byun; S Mohan; M Yoo; C Sexton; D J Baylink; X Qin
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

7.  First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).

Authors:  Lorraine Dugoff; John C Hobbins; Fergal D Malone; T Flint Porter; David Luthy; Christine H Comstock; Gary Hankins; Richard L Berkowitz; Irwin Merkatz; Sabrina D Craigo; Ilan E Timor-Tritsch; Steven R Carr; Honor M Wolfe; John Vidaver; Mary E D'Alton
Journal:  Am J Obstet Gynecol       Date:  2004-10       Impact factor: 8.661

8.  Effect of in vitro fertilization on human chorionic gonadotropin serum concentrations and Down's syndrome screening.

Authors:  S Heinonen; M Ryynänen; P Kirkinen; M Hippeläinen; S Saarikoski
Journal:  Fertil Steril       Date:  1996-09       Impact factor: 7.329

9.  Cell-free fetal DNA concentration in plasma of patients with abnormal uterine artery Doppler waveform and intrauterine growth restriction--a pilot study.

Authors:  Elisabetta Caramelli; Nicola Rizzo; Manuela Concu; Giuliana Simonazzi; Paolo Carinci; Corrado Bondavalli; Luciano Bovicelli; Antonio Farina
Journal:  Prenat Diagn       Date:  2003-05       Impact factor: 3.050

10.  Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR.

Authors:  Kirby L Johnson; Kimberly A Dukes; John Vidaver; Erik S LeShane; Idania Ramirez; William D Weber; Farideh Z Bischoff; Sinuhe Hahn; Arun Sharma; Dianne X Dang; Lisa M Hire; Diana W Bianchi; Joe Leigh Simpson; Wolfgang Holzgreve; Sherman Elias; Katherine W Klinger
Journal:  Clin Chem       Date:  2004-01-12       Impact factor: 8.327

View more
  3 in total

Review 1.  Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis.

Authors:  Stephanie A Devaney; Glenn E Palomaki; Joan A Scott; Diana W Bianchi
Journal:  JAMA       Date:  2011-08-10       Impact factor: 56.272

2.  Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.

Authors:  Roberto Romero; Eunjung Jung; Tinnakorn Chaiworapongsa; Offer Erez; Dereje W Gudicha; Yeon Mee Kim; Jung-Sun Kim; Bomi Kim; Juan Pedro Kusanovic; Francesca Gotsch; Andreea B Taran; Bo Hyun Yoon; Sonia S Hassan; Chaur-Dong Hsu; Piya Chaemsaithong; Nardhy Gomez-Lopez; Lami Yeo; Chong Jai Kim; Adi L Tarca
Journal:  Am J Obstet Gynecol       Date:  2022-09-03       Impact factor: 10.693

Review 3.  Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects.

Authors:  Peter Benn
Journal:  J Clin Med       Date:  2014-05-21       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.